Evotec receives $10M milestone as BMS advances novel protein degrader into clinic
Evotec (NASDAQ:EVO) announced today that it will receive a $10 million milestone payment from Bristol Myers Squibb (NYSE:BMY) following the start of a Phase 1 clinical trial for BMS-986506.








_1362640_640x360_2492670531783-640x360.webp&w=3840&q=75)


